These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 3677119

  • 1. Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
    Gundersen S.
    Cancer Treat Rep; 1987 Nov; 71(11):997-9. PubMed ID: 3677119
    [No Abstract] [Full Text] [Related]

  • 2. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, Italian Cooperative Oncology Group.
    Cancer; 2000 Dec 15; 89(12):2630-6. PubMed ID: 11135225
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B.
    Carey RW, Anderson JR, Green M, Ellison RR, Nathanson L, Kennedy BJ.
    Cancer Treat Rep; 1986 Mar 15; 70(3):329-31. PubMed ID: 2420443
    [No Abstract] [Full Text] [Related]

  • 7. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF, McClay ME, Monroe L, Baron PL, Cole DJ, O'Brien PH, Metcalf JS, Maize JC.
    Br J Cancer; 2000 Jul 15; 83(1):16-21. PubMed ID: 10883662
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group.
    Verschraegen CF, Kleeberg UR, Mulder J, Rumke P, Truchetet F, Czarnetzki B, Rozencweig M, Thomas D, Suciu S.
    Cancer; 1988 Sep 15; 62(6):1061-5. PubMed ID: 3409184
    [Abstract] [Full Text] [Related]

  • 10. Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.
    Oratz R, Speyer JL, Green M, Blum R, Wernz JC, Muggia FM.
    Cancer Treat Rep; 1987 Sep 15; 71(9):877-8. PubMed ID: 3621224
    [No Abstract] [Full Text] [Related]

  • 11. [Chemotherapy of malignant melanoma].
    Ishihara K, Yamazaki N, Asano K.
    Gan To Kagaku Ryoho; 1993 Aug 15; 20(10):1287-92. PubMed ID: 7688498
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of vinblastine, bleomycin, and cisplatin (VBP) followed by dacarbazine and mitolactol in metastatic melanoma.
    Richman SP, Woodcock TM, Kubota TT, Blumenreich MS, Gentile PS, Allegra JC.
    Cancer Treat Rep; 1984 Nov 15; 68(11):1395-6. PubMed ID: 6209008
    [No Abstract] [Full Text] [Related]

  • 13. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
    Ringborg U, Jungnelius U, Hansson J, Strander H.
    Am J Clin Oncol; 1990 Jun 15; 13(3):214-7. PubMed ID: 2346126
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of the combination of vinblastine plus cisplatin administered by continuous 120-hour infusion for patients with advanced malignant melanoma.
    Creagan ET, Ahmann DL, Schutt AJ, Schaid DJ.
    Cancer Treat Rep; 1987 Jun 15; 71(7-8):769-70. PubMed ID: 3607788
    [No Abstract] [Full Text] [Related]

  • 15. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
    Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C, Talbot DC, Ganesan TS, Harris AL.
    Br J Cancer; 2000 Jun 15; 82(11):1759-63. PubMed ID: 10839287
    [Abstract] [Full Text] [Related]

  • 16. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
    Friedman MA, Kaufman DA, Williams JE, Resser KJ, Rosenbaum EH, Cohen RJ, Glassberg AB, Blume MR, Gershow J, Chan EY.
    Cancer Treat Rep; 1979 Mar 15; 63(3):493-5. PubMed ID: 371802
    [No Abstract] [Full Text] [Related]

  • 17. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 18. [48-hour continuous infusion of vindesine (followed by cisplatin) in advanced lung cancer. Chronopharmacokinetic data and clinical efficacy].
    Focan C, Doalto L, Mazy V, Levi F, Bruguerolle B, Cano JP, Rahmani R, Hecquet B.
    Bull Cancer; 1989 Apr 20; 76(8):909-12. PubMed ID: 2620124
    [No Abstract] [Full Text] [Related]

  • 19. [Effect of cis-diammine dichloroplatinum, vindesine sulfate combination chemotherapy for advanced esophageal carcinoma].
    Akazawa S, Kitagawa H, Nakagawa T, Fujiki T, Kanda Y, Futatsuki K, Sampi K, Fujita K.
    Gan To Kagaku Ryoho; 1984 May 20; 11(5):1018-23. PubMed ID: 6539098
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S.
    Anticancer Res; 2000 May 20; 20(3B):1985-90. PubMed ID: 10928138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.